Stock Research for BIIB


Featured Broker: Ally Invest

Get the due diligence for another stock.


BIIB Stock Chart & Research Data

The BIIB chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BIIB chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


BIIB Due diligence Resources & Stock Charts

The BIIB stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BIIB Detailed Price Forecast - CNN Money CNN View BIIB Detailed Summary - Google Finance
Yahoo View BIIB Detailed Summary - Yahoo! Finance Zacks View BIIB Stock Research & Analysis -

Stock Analysis

TradeIdeas View BIIB Trends & Analysis - Trade-Ideas Barrons View BIIB Major Holders - Barrons
NASDAQ View BIIB Call Transcripts - NASDAQ Seeking View BIIB Breaking News & Analysis - Seeking Alpha
Spotlight View BIIB Annual Report - OTC Report View BIIB OTC Short Report -
TradeKing View BIIB Fundamentals - TradeKing Charts View BIIB SEC Filings - Bar Chart
WSJ View Historical Prices for BIIB - The WSJ Morningstar View Performance/Total Return for BIIB - Morningstar
MarketWatch View the Analyst Estimates for BIIB - MarketWatch CNBC View the Earnings History for BIIB - CNBC
StockMarketWatch View the BIIB Earnings - StockMarketWatch MacroAxis View BIIB Buy or Sell Recommendations - MacroAxis
Bullish View the BIIB Bullish Patterns - American Bulls Short Pains View BIIB Short Pain Metrics -

Social Media Mentions

StockTwits View BIIB Stock Mentions - StockTwits PennyStocks View BIIB Stock Mentions - PennyStockTweets
Twitter View BIIB Stock Mentions - Twitter Invest Hub View BIIB Investment Forum News - Investor Hub
Yahoo View BIIB Stock Mentions - Yahoo! Message Board Seeking Alpha View BIIB Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for BIIB - Insider Cow View Insider Transactions for BIIB - Insider Cow
CNBC View BIIB Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BIIB - OTC Markets
Yahoo View Insider Transactions for BIIB - Yahoo! Finance NASDAQ View Institutional Holdings for BIIB - NASDAQ

Stock Charts

FinViz View BIIB Stock Insight & Charts - StockCharts View BIIB Investment Charts -
BarChart View BIIB Stock Overview & Charts - BarChart Trading View View BIIB User Generated Charts - Trading View

Latest Financial News for BIIB

5 biotech stocks that could be the next big winners
Posted on Monday March 25, 2019

Biotech stocks are some of the most exciting investments on Wall Street. When one company develops a successful treatment for a complex condition, shares can surge overnight and attract buyout interest from Big Pharma. Case in point: Biotech giant Biogen (BIIB) imploded roughly 30% on Thursday after announcing it is canceling its Alzheimer’s drug efforts after poor drug trials.

Is It Safe to Buy Biogen Stock Right Now?
Posted on Sunday March 24, 2019

On Thursday, shares of Biogen (NASDAQ:BIIB) were hammered, falling more than 29% in just one session. Biogen stock was again under pressure on Friday, falling almost 3% on the day. The move puts the stock down massively on the week and below key support.Source: Biogen via YouTubeBut what's got BIIB stock under pressure in the first place?On Thursday morning, Biogen announced that it and development partner Eisai would terminate two stage 3 clinical trials for their Alzheimer's treatment, aducanumab. As InvestorPlace's Aaron Levitt put it (linked above): "The massive drop was truly an unsettling surprise for BIIB shareholders as the drug was seen as a multi-billion blockbuster and game-changing medication for treating the disease. It really did come out of nowhere."InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt has many investors trapped above at higher prices, with some investors wondering if now's the time to get long. Let's digest the charts here. Trading Biogen Stock Click to EnlargeDespite axing what many were hoping would be a robust treatment, Biogen's fundamentals are still intact. However, the charts are not. Above is a five-year weekly chart highlighting just how much technical damage was dealt out over the past two days. * The 10 Best ETFs to Buy in the Second Quarter It's crazy how much can change in one day. With Biogen stock, we have the stock plunging through the 10-week, 50-week and 200-week moving averages, as well as falling below key support. $250 has been long-time support, buoying BIIB stock for much of the past five years. The exception came in 2016, when Biogen stock broke below this mark for about six months.When that happened, $230 stood tall, but even that mark failed to prop up Biogen this time. What are investors going to do? A retest of the lows near $210 certainly seems to be in the cards now, but the rebound is what has me concerned. Should BIIB stock bounce, bulls need to see what role $250 plays. If this mark acts as resistance, Biogen could be a tough one to own for a while. If it gives way and the stock is able to get back above this mark, then BIIB has a chance to reclaim its prior range.Aggressive bulls could justify a new position in Biogen stock with a stop-loss near the 2016 lows. Conservative bulls may want to wait for a possible retest of those lows or at least a further decline before starting to nibble.In either case, $250 will be an important test at some point. Valuing BIIB StockDespite the technical thrashing, the fundamentals still look attractive. Revenue estimates call for just 2.2% growth this year to $13.75 billion, while earnings expectations call for 9.4% growth to $28.67 per share. That leaves Biogen stock trading at a very low valuation, at just 7.7 times this year's earnings.It would be one thing if Biogen had negative earnings and revenue expectations for this year and next year. But that's not the case, while cash flow generation remains strong. Over the past 12 months, BIIB has generated free cash flow of more than $5.3 billion. That leaves BIIB stock trading at about 8.4 times its trailing free cash flow.Guys, these aren't expensive numbers here, even with the disappointing Alzheimer's news and the lack of robust growth. That said, the discount to the stock price isn't surprising. Just look at a company like Celgene (NASDAQ:CELG), which has forecast for double-digit earnings and revenue growth this year and next year, yet trades at just 8.5 times this year's earnings. And that's with a pending buyout offer from Bristol-Myers Squibb (NYSE:BMY).I would rather be long CELG (and for that matter, I am) than Biogen stock at this point. That said, long-term investors could justify soon nibbling a position in the latter as it nears a potential capitulation low.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, he was long CELG. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio Compare Brokers The post Is It Safe to Buy Biogen Stock Right Now? appeared first on InvestorPlace.

Biogen stock plummets 28% after company halts Alzheimer’s trials
Posted on Sunday March 24, 2019

Shares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an investigational drug designed to treat symptoms of early Alzheimer’s disease.

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Posted on Saturday March 23, 2019

Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ: SAGE )'s drug to treat postpartum depression and Jazz Pharmaceuticals ...

Stock Market & Investing Books

Enter a stock symbol to view the stock details.